Pure Global

Long-term Safety of TPN171H Tablet in Erectile Dysfunction. - Trial NCT06301854

Access comprehensive clinical trial information for NCT06301854 through Pure Global AI's free database. This Phase 3 trial is sponsored by Vigonvita Life Sciences and is currently Recruiting. The study focuses on Erectile Dysfunction. Target enrollment is 400 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06301854
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06301854
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Long-term Safety of TPN171H Tablet in Erectile Dysfunction.
A Multicenter, Open Study to Evaluate the Long-term Safety and Efficacy of TPN171H in Patients With Erectile Dysfunction

Study Focus

Erectile Dysfunction

TPN171H

Interventional

drug

Sponsor & Location

Vigonvita Life Sciences

Hefei,Beijing,Beijing,Guangzhou,Guangzhou,Guangzhou,Shantou,Shantou,Shenzhen,Guilin,Guiyang,Qingyuan,Shijiazhuang,Xingtai,Zhengzhou,Zhengzhou,Wuhan,Wuhan,Changsha,Loudi,Yueyang,Suzhou,Nanchang,Yichang, China

Timeline & Enrollment

Phase 3

Apr 12, 2024

Apr 30, 2025

400 participants

Primary Outcome

Incidence of adverse events (AE) and adverse drug reactions (ADRs) during treatment observation.

Summary

This is a multicenter, open study to evaluate the long-term safety and efficacy of TPN171H in
 men with erectile dysfunction.

ICD-10 Classifications

Orgasmic dysfunction
Other disorders of penis
Other specified disorders of penis
Sexual dysfunction, not caused by organic disorder or disease
Testicular dysfunction

Data Source

ClinicalTrials.gov

NCT06301854

Non-Device Trial